Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Core Viewpoint - Journey Medical Corporation is preparing for the commercial launch of Emrosi™, an FDA-approved treatment for rosacea, with a focus on establishing it as a new oral standard of care for adult patients [1][2]. Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company that specializes in marketing FDA-approved prescription products for dermatological conditions [9]. - The company currently markets seven branded and two generic products aimed at treating common skin conditions [9]. - Founded by Fortress Biotech, Inc., Journey Medical is located in Scottsdale, Arizona [9]. Product Information - Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) was approved by the FDA in November 2024 for treating inflammatory lesions of rosacea in adults [1]. - The product was developed in collaboration with Dr. Reddy's Laboratories Ltd. [1]. Launch Plans - The management team will host a conference call on February 5, 2025, to discuss the commercial launch plan for Emrosi, including pre-commercial activities and launch timing [1][3]. - The company is finalizing the manufacturing of launch quantities for the U.S. market and preparing its dermatology-focused sales force for the rollout [2]. Market Context - Rosacea is a chronic skin condition affecting over 16 million Americans and approximately 415 million people worldwide, primarily seen in adults aged 30 to 50 [8]. - The condition significantly impacts patients' self-confidence and social interactions, with many reporting adverse effects on their professional lives [8].